Transaction DateRecipientSharesTypePriceValue
27th October 2020Funds Management Llc Fairmount87,891Other acquisition or disposition$0.00
27th October 2020Funds Management Llc Fairmount438,502Other acquisition or disposition$0.00
18th August 2020Healthcare Capital Partners Iii, L.P. Venrock101,000Open or private purchase$2.62$264,620.00
17th August 2020Healthcare Capital Partners Iii, L.P. Venrock250,000Open or private purchase$2.57$642,500.00
14th August 2020Healthcare Capital Partners Iii, L.P. Venrock100,000Open or private purchase$2.30$230,000.00
6th July 2020John L. Green109,459Exercise of derivative$0.00
6th July 2020Funds Management Llc Fairmount5,088,497Other acquisition or disposition$0.00
6th July 2020John L. Green31,873Payment by withholding$2.20$70,120.60
6th July 2020Funds Management Llc Fairmount1,147,406Other acquisition or disposition$0.00
15th June 2020Healthcare Capital Partners Iii, L.P. Venrock1,500,000Open or private purchase$7.54$11,310,000.00
Unum Therapeutics
Unum Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.


Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies.


Ticker: UMRX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1622229
Employees: 56
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals